Aventis pharma
Download
1 / 13

Aventis Pharma - PowerPoint PPT Presentation


  • 605 Views
  • Updated On :

Aventis Pharma. Aventis Pharma. Prescription drugs Aventis Pharma. Vaccines Aventis Pasteur. Therapeutic proteins Aventis Behring. Diagnostics Dade Behring. Aventis Pharma. Key Figures. 92, 500 employees – 80% in Pharma 16 Bn€ Pharma sales – 5th in top 10

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about 'Aventis Pharma' - Olivia


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
Aventis pharma l.jpg
Aventis Pharma


Aventis pharma2 l.jpg

Aventis Pharma

Prescription drugs

Aventis Pharma

Vaccines

Aventis Pasteur

Therapeutic proteins

Aventis Behring

Diagnostics

Dade Behring

Aventis Pharma


Key figures l.jpg
Key Figures

  • 92, 500 employees – 80% in Pharma

  • 16 Bn€ Pharma sales – 5th in top 10

  • Strong & growing US presence with >35% sales

  • 19,000 member sales force

  • 16.8% R&D expenditure; 6500 scientists & technicians worldwide

  • 15% of R&D expenditure dedicated to alliances; about 50 major biotech collaborations; about 250 academic collaborations


Drug innovation approval r d disease groups supported by powerful technology platforms l.jpg

*

Gene Therapy

Drug Innovation & Approval (R&D)Disease Groups supported by powerful technology platforms

  • ~6500 scientists & technicians worldwide

- Oncology, - Infectious Diseases

- Neurodegenerative Diseases, (Parkinson & Alzheimer),

Asian Drug Devt Ctr

European Drug Devt Ctr

US

Global and US Drug Devt Ctr

  • - Immunology platform - Respiratory diseases - RA - CNS

JAPAN

FRANCE

GERMANY

  • CV- Metabolic Diseases, - Osteoarthritis, Thrombosis


Slide5 l.jpg

CDG Airport

SEINE ST DENIS

Romainville

HAUTS DE SEINE

PARIS

Vitry-Alfortville

Croix de Berny

VAL DE MARNE

ESSONNE

Evry

5 km

Drug Innovation & Approval in France

  • Paris Research Centre

  • European Drug Devt Centre

  • ~2800 scientists & technicians


New drug discovery technologies l.jpg

Target

Selection

Lead

Identification

Candidate

Identification

Preclinical

Candidate

Identification

PhI / IIa

PhIIb

PhIII

Regulatory

Review

Integrated Data and Knowledge Management

New drug discovery technologies

Functional Genomics

TechnologiesDNA chips

Proteomics, cellular & animal models..

Lead Identification TechnologiesMedChem, ChemBiol, Structural Genomics and Biology….

Technologies for Exploratory DevelopmenteADMET, TGX, PGX, Biomarkers….

Technologies for Global Rapid submissionse-submissions…..


Integration of genomics technologies disease biology platforms l.jpg

Metabolism OncologyCNS / ND Cardiovascular Rheumatoid Arthritis Osteoarthritis - DJD Respiratory Diseases Anti-Infectives Immunology platform

Aventis Genomics Centers

DiseaseBiologyPlatforms

GenomicsTechnologyPlatforms

External Collaborations & Networks

External Collaborations & Networks

Targets relevant to disease

Integration of Genomics Technologies &Disease Biology Platforms


Slide8 l.jpg

Key Challenges

  • The post-human genome sequence race

    • functional genomics

    • proteomics

    • protein structure prediction

    • re-thinking chemical approaches

    • re-thinking clinical development

  • Continuous integration of technologies (alliances and partnering), information and knowledge (knowledge networks)

  • Availability of skilled work force (right skill-set and mind-set)


Slide9 l.jpg

Post-doc Opportunities in Aventis Pharma, France

In partnership with the European Commission: 12 Marie Curie Industry Host Fellowships

for a 2 year period.

  • Parkinson’s Disease Gene Targets (3 positions)

  • Molecular Modeling and High Throughput Medicinal Chemistry (3 positions)

  • From Protein-Protein Interactions (yeast 2H) to Lead Discovery Process (3positions)

  • Bio-Informatics in Toxicogenomics (1 position)

  • Cardiovascular Gene Therapy (1 position)

  • Adenoviral Vector-based system for Functional Genomics (1 position)

Immediate Starting Date


Slide10 l.jpg

Post-doc Opportunities in Aventis Pharma, France

In partnership with the European Commission

The position are open to members of the E.C. or resident of associated countries for more than 5 years.

The age limit at the time of selection is 35 years old.

Austria,

Belgium,

Bulgaria,

Czech republic,

Denmark,

Estonia,

Finland,

Germany

Greece,

Hungary,

Iceland,

Ireland,

Israel,

Italy,

Latvia,

Liechtenstein

Lithuania,

Luxembourg,

Netherlands,

Norway,

Poland,

Portugal,

Republic of Cyprus,

Romania

Slovakia,

Slovenia,

Sweden,

Spain,

United Kingdom

However French citizens are ineligible as well as those who have been resident in France for more than 12 out of the last 24 months.


Slide11 l.jpg

Post-doc Opportunities in Aventis Pharma, France

Coming soon

9 post-doctoral positions

  • Statistics for Pharmacogenetics

  • Kinases in Oncology and Neurodegenerative diseases

  • Gene Transfer in Angiogenesis

  • Genomic Studies for the glial-neuronal interactions


Slide12 l.jpg

Post-doc Opportunities in Aventis Pharma, France

  • Project Team

  • Networking

  • Publications/patents

  • Confidentiality

  • 250 KF/year (38KEuros/year)

  • Social security included

  • 26 + 12 days holiday


Slide13 l.jpg

Post-doc Opportunities in Aventis Pharma, France

Come and join us on the Aventis stand to learn more about our post-doctoral opportunities !

[email protected]


ad